PDCD1 and B-cell chronic lymphocytic leukemia: However, the underlying immune dysfunction caused by CLL, the ongoing immunotherapy with anti-PD1 therapy, MDSC depletion by RT and the advanced age of the patient may all have contributed to the observation of an atypical immune response to cancer therapy.